Private Wealth Partners LLC reduced its position in CareDx Inc (NASDAQ:CDNA) by 67.0% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 308,000 shares of the company’s stock after selling 626,500 shares during the quarter. Private Wealth Partners LLC owned about 0.85% of CareDx worth $3,770,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Strs Ohio acquired a new position in CareDx in the 2nd quarter valued at $116,000. Metropolitan Life Insurance Co. NY acquired a new position in CareDx in the 2nd quarter valued at $139,000. Citadel Advisors LLC acquired a new position in CareDx in the 1st quarter valued at $152,000. Voya Investment Management LLC acquired a new position in CareDx in the 2nd quarter valued at $153,000. Finally, Fox Run Management L.L.C. acquired a new position in CareDx in the 2nd quarter valued at $178,000. 72.84% of the stock is currently owned by institutional investors.

NASDAQ:CDNA opened at $26.04 on Tuesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.83 and a current ratio of 2.16. CareDx Inc has a fifty-two week low of $2.77 and a fifty-two week high of $27.55. The firm has a market cap of $950.82 million, a PE ratio of -33.82 and a beta of 0.90.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings results on Thursday, August 9th. The company reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.03. CareDx had a negative net margin of 121.92% and a negative return on equity of 108.99%. The business had revenue of $17.82 million for the quarter, compared to analysts’ expectations of $15.30 million. equities research analysts expect that CareDx Inc will post -0.94 earnings per share for the current fiscal year.

In other news, COO Mitchell J. Nelles sold 39,649 shares of the company’s stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $12.48, for a total transaction of $494,819.52. Following the transaction, the chief operating officer now directly owns 89,639 shares of the company’s stock, valued at approximately $1,118,694.72. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Michael Brian Bell sold 16,355 shares of the company’s stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $25.06, for a total transaction of $409,856.30. Following the transaction, the chief financial officer now directly owns 52,238 shares in the company, valued at $1,309,084.28. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 92,962 shares of company stock worth $1,594,372. Corporate insiders own 3.40% of the company’s stock.

Several equities analysts have issued reports on CDNA shares. BidaskClub raised shares of CareDx from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 25th. Piper Jaffray Companies reissued an “overweight” rating and issued a $17.00 price objective on shares of CareDx in a research note on Wednesday, June 6th. TheStreet cut shares of CareDx from a “c-” rating to a “d” rating in a research note on Monday, June 11th. HC Wainwright cut shares of CareDx from a “buy” rating to a “neutral” rating and set a $15.00 price objective on the stock. in a research note on Tuesday, June 19th. Finally, Zacks Investment Research cut shares of CareDx from a “hold” rating to a “sell” rating in a research note on Friday, July 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company’s stock. CareDx presently has an average rating of “Buy” and an average target price of $18.90.

About CareDx

CareDx, Inc, a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics.

Featured Story: Leveraged Buyout (LBO)

Institutional Ownership by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.